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Abstract 
Objective: Systolic and diastolic blood pressure (SBP and DBP) increase significantly until around 
55 years, when SBP increases, DBP decreases. Whether the rates of change of SBP and DBP with age 
exhibit a similar dissociation has never been investigated.  
Design and participants: D.E.S.I.R., a 9-year longitudinal study included 2,278 men and 2,314 women, 30-
65 years and SBP, DBP, and other cardio-metabolic risk factors were determined every three years.  
Results: Both SBP and DBP increased with age, more rapidly in women than in men. SBP and DBP were 
higher in the presence of risk factors (except smoking) but the increases with age were similar. For the 
rates of change, whereas ∆SBP increased linearly with age, ∆DBP declined as early as 45 years. This 
finding was not influenced by gender, menopause or other risk factors but was significantly attenuated in 
the presence of hypertension at baseline, whether treated or not, and mainly in men.  
Conclusions: DBP increases with age between 30 and 60 years, ∆DBP tends to be markedly reduced as 
early as 45 years, in contrast with ∆SBP. Consequences for the understanding of vascular aging and 
antihypertensive therapy remain to be explored. 
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Introduction 
Antihypertensive therapy has considerably improved cardiovascular (CV) risk in people treated for 
hypertension [1,2].The major beneficial effect of CV prevention has been for stroke, congestive heart 
failure and renal insufficiency. Less progress has been made for the prevention of coronary heart disease. 
Despite an adequate drug treatment, a significant residual coronary risk is commonly observed during the 
long-term follow-up of hypertensive subjects [3]. Furthermore, a very particular haemodynamic pattern is 
frequently observed during antihypertensive therapy: while diastolic blood pressure (DBP) is adequately 
controlled (≤ 90 mm Hg), systolic blood pressure (SBP) remains frequently elevated above 140 mm Hg [4]. 
This haemodynamic profile, which is commonly observed in the elderly, even in the total absence of 
antihypertensive drug treatment, is traditionally attributed to an age-induced increase in arterial stiffness 
together with the presence of altered wave reflections [5, 6]. This observation suggests that, during chronic 
drug therapy, consistent interactions occur in the long term between aging, high SBP and/or DBP, and 
antihypertensive treatment. Such interactions are difficult to clarify because the duration of therapeutic 
trials approximates 3–5 years, while that of antihypertensive therapy is close to 30 years (and even longer). 
Taken together, these findings indicate the need to develop studies evaluating in parallel the changes of 
brachial SBP and DBP and the progressive development of vascular aging. 
D.E.S.I.R. (Data from an Epidemiologic Study on the Insulin Resistance syndrome) is a cohort of more 
than 4,500 men and women aged 30–65 years at inclusion, who were investigated every 3 years for a total 
of 9 years follow-up [7]. From this long-term survey, it is possible to evaluate not only the mean values of 
SBP and DBP with age, but also the rate of change of this classical relationship, i.e. the change in SBP or 
DBP per unit year (∆SBP or ∆DBP), in each gender, according to age at baseline. From the present 
D.E.S.I.R. study and other investigations [7-12], we know that the mean values of SBP and DBP increase 
progressively with age but also that, above 50-60 years of age, mean values of SBP increase with age while 
mean values of DBP begin to lower. Our working hypothesis is that the evolution of ∆SBP and ∆DBP also 
differ consistently, particularly ∆DBP, and that this process might influence the effects of drug treatment. 
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The role of major cardiovascular risk factors such as smoking, blood pressure (BP), body weight, plasma 
cholesterol and glucose was systematically investigated. 
 
Methods 
Participants 
The main objective of the 9-year longitudinal study D.E.S.I.R., was to clarify the development of the 
insulin resistance syndrome. It is not a population based study, but a study of individuals who volunteered 
for a heath check-up and who were willing to participate in a 9-year study. Participants were recruited over 
the period 1994 to 1998 from ten Health Examination Centres from volunteers insured by the French Social 
Security system, which offers periodic health examinations free of charge: 85% of the French population is 
eligible for these examinations [7]. The total population in the geographical area of our study was over four 
million inhabitants, and 90,000 individuals benefit from such examinations each year.. The protocol was 
approved by the CCPPRB (“Comité Consultatif de la Protection des Personnes pour la Recherche 
Biomédicale”) of Bicêtre Hospital, Paris, and participants signed an informed consent.  
The analysis included 2,278 men and 2,314 women, aged 30 to 65 years, with measures at baseline for all 
studied parameters and at least one other measure of BP at one of the follow-up examinations at 3, 6 and 9 
years after inclusion.  
Measures  
Arterial blood pressures were measured in a supine position after 5 minutes rest. Both at inclusion and at 
the 3-year follow-up examination, a mercury sphygmomanometer was used and at the 6- and 9-year 
examinations, an OMRON HEM-705CP. According to the validation study by O’Brien et al. [13] the 
OMRON HEM-705O device measures SBP 2 mmHg and DBP 1 mmHg lower than a standard mercury 
sphygmomanometer; we added these differences to the Omron measured blood pressures. Participants were 
lightly clad, and weight and height were measured, and body mass index (BMI = weight /height2 (kg/m2)) 
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calculated. The waist was measured as the smallest circumference between the lower ribs and the iliac 
crest. Hypertensive treatment and hormone replacement therapy were recorded. 
All biochemical measurements were from one of four health-centre biological laboratories located in 
France at Blois, Chartres, La Riche or Orléans. Total cholesterol, HDL-cholesterol and triglycerides, were 
assayed by DAX 24 (Bayer Diagnostics, Puteaux, France) or KONE (Evry, France). The fasting plasma 
glucose, measured by the glucose-oxidase method, was applied to fluoro-oxalated plasma using a 
Technicon RA1000 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta device (Konelab, Evry, 
France). The inter-laboratory variability was assessed monthly on normal and pathological values for each 
biologic variable, the coefficients of variation for laboratories being lower than 6% over the inclusion 
period.  
The examining physician noted the menopausal status of the women at each of the four examinations; no 
hormonal tests to validate this status were carried out. The information was inconsistent for some of the 
women, so that we were able to class only 2,202 of the 2,314 women: 878 were postmenopausal at entry 
into the study, 575 were menopaused during the study, and 749 were premenopausal at the end of the nine-
year follow-up. Hormone replacement therapy was taken by 853 women, of whom 361 were 
postmenopausal: 69 women did not provide information about hormonal replacement therapy. 
Cardio-metabolic risk factors were defined as follows [14]: 
- Overweight: BMI ≥ 25 kg/m2; 
- Abdominal obesity: waist circumference > 102 / 88 cm, men/women; 
- High blood pressure: SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg; 
- Smoker: current smoker; 
- Hyper-cholesterolaemia: cholesterol: ≥ 5.70 mmol/l; 
- Hyper-triglyceridaemia: triglycerides ≥ 1.69 mmol/l; 
- Hypo-HDL-cholesterolaemia: HDL-cholesterol < 1.04 / 1.29 mmol/l, men/women; 
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Glucose status (diabetic: treated or fasting plasma glucose ≥ 7.0 mmol/l, impaired fasting glucose: fasting 
plasma glucose between 6.1 and 6.9 mmol/l, normal: fasting plasma glucose < 6.1 mmol/l.) 
Statistical methods 
The characteristics of the individuals, their SBP, DBP are presented at inclusion in the study, according to 
sex, by means (standard deviations) and percentages. We studied, the SBP and DBP of each individual, 
over the 9 years of follow-up, by two metrics: their values at baseline, and their rate of change per year, 
∆SBP, ∆DBP, assuming a linear relation over the time period.  
The relations between baseline SBP and DBP mean values and age, called “SBP and DBP mean values”, 
were modelled by linear regression with respect to baseline age (as a continuous parameter) [11], and 
likelihood ratio tests determined whether these relations were better described by a linear or a curvilinear 
relation with age, by the addition of a squared term in age. These relations are shown graphically, with the 
observed data as points on the graphs by 5-year age groups, along with the modelled curve. We compared 
the relations between men and women, using likelihood ratio tests and present the regression relations with 
a) separate curves or lines, or with b) a combined curve or line if they did not differ significantly according 
to sex. These relations were also studied according to strata of cardio-metabolic risk factors, presence of 
anti-hypertensive drug treatment, menopausal status and hormone replacement therapy. For the different 
classes of antihypertensive agents, the numbers treated were too small to allow an adequate statistical 
evaluation (Table 1). 
The changes per year in SBP and DBP were studied according to age at entry into the study, and by sex.  
For each subject a slope, or a change per year, was calculated for SBP and DBP over the nine years of the 
study, called “∆SBP” and “∆DBP”. These values are shown graphically by 5-year age groups and modelled 
by regression analysis, according to age at entry into the cohort, with tests for linearity in age. These 
relations are shown graphically. We compared the relations between men and women using likelihood ratio 
tests and present models with a) separate curves or lines, or with b) a combined curve or line if they did not 
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differ according to sex. These relations were also studied according to strata of cardio-metabolic risk 
factors and other factors indicated above. 
A change in the intercept without any change in slope indicated a shift of the curve. A change in the slope 
indicated a change in the sensitivity of the system. 
Analyses used SAS Version 8.2 (SAS Institute Inc. Cary, NC USA).  
Results 
General characteristics of the studied population  
Table 1 shows the mean value of clinical and biological parameters and their evolution per year, assuming 
a linear progression. For the same age, and a similar percentage of antihypertensive drug therapy, women 
had a significantly lower mean weight, height, waist circumference, SBP and DBP than men, but a higher 
mean heart rate. Changes per year in weight and waist circumference were higher in women than in men, 
but an opposite finding was observed for the changes per year in SBP and DBP. Changes in biological 
parameters slightly differed between men and women during the follow-up. Antihypertetnsive treatment 
was mainly with beta blockers and ACE inhibitors; at inclusion angiotensin receptor blockers were not 
available. 
Mean values of brachial SBP and DBP at inclusion by age and sex  
At each age range at inclusion, the mean SBP was lower in women than in men (Fig. 1A). However, both 
in men and women, SBP increased linearly and significantly with age, at a higher rate (P < 0.0001) and 
with a lower intercept (P < 0.0001) in women than in men. In women, this latter finding was even more 
pronounced in postmenpause than in the premenopause; women who became menopaused during the 
follow-up having the greatest increase (data not shown). For SBP, the same model was studied in 
populations divided according to values of cardio-metabolic risk factors (BMI, BP status, smoking, total 
cholesterol, glucose status as well as waist circumference, HDL-cholesterol, triglycerides, menopause (data 
not shown for the latter factors)). Higher intercepts (except with smoking) were noted in the presence of the 
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risk factors, antihypertensive drug treatment and hormonal replacement therapy (Table 2). There was one 
other exception: when individuals were divided according to BP status, for men and women without high 
BP at inclusion, there was little variation in mean SBP with age (Fig. 2A); for men and for women with 
high BP the intercepts were higher, with almost identical SBP-age coefficients.  
There was a significant increase in DBP with age (Fig. 1B), with lower values in women than in men at 
each age range. In men and women, the best model was curvilinear, with a significantly steeper slope with 
age in women than in men. These relations were little changed in the presence of other cardiovascular risk 
factors or according to menopause (Table 2): when one of these risk factors was increased, equations of the 
model generally did not change their slope but had a significantly higher intercept, except for smoking in 
men. This was also true for men and women with high and with low BP where there were similar relations 
between DBP and age (Table 2, Fig. 2B). 
In summary, the mean values of SBP and DBP increased with age, both in men and women. The increase 
in SBP and DBP with age was steeper in women than in men, particularly in postmenopausal women. The 
model relating BP to age was linear for SBP and curvilinear for DBP. The presence of other cardiovascular 
risk factors changed little the slope with age but was associated with a consistent increase in the intercept, 
except for smoking. These conclusions held when account was taken of blood pressure treatment (Table 2). 
Mean change of SBP and DBP per year (∆SBP and ∆DBP) by age at inclusion and by sex  
Figure 3 shows the mean change per year of SBP, ∆SBP (Fig. 3A), and of DBP, ∆DBP (Fig. 3B), 
according to age and sex in the overall population. 
For  ∆SBP in the total population (Fig. 3A), the mean change per year increased significantly with age, 
with higher values (P < 0.0001) in men than in women. There was a similar slightly curvilinear model 
(P < 0.05) in both sexes with the increase being less pronounced at higher ages. The presence of the factors 
cited above did not modify this description (Table 3), and there was no longer a significant curvature when 
the population was divided according to these strata, with an exception regarding BP status. For men with 
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or without high BP at inclusion, there was an increase in ∆SBP with age of 0.4 mmHg per 10 years of age, 
with a similar increase for women (Table 3). However, men and women with high BP had respectively, a 
yearly change 0.82 and 0.89 mmHg lower than those without high BP at inclusion. 
The ∆DBP by age model exhibited a very particular aspect (Fig. 3B), as it was identical and curvilinear for 
both men and women, with a maximum value around 45 years of age, after which ∆DBP decreased with 
age, showing negative values, after the age of 60 years. The finding was unaffected by the presence of the 
various covariates (Table 3), with the exception of high BP. In all of these cases the ∆DBP curves were 
separated, with the men and women at lower risk having a higher ∆DBP. The ∆DBP-age relation remained 
curvilinear only for the men. This result indicates that over 45 years of age, ∆DBP is reduced more and 
more with increasing age, particularly in those with high BP at baseline.  
In summary, the relation between age and ∆SBP and ∆DBP differed markedly, increasing with age for 
∆SBP and decreasing for ∆DBP. This latter observation was not influenced by sex, or other possible 
confounders, excepting for antihypertensive treatment in women (Table 3). 
 
Discussion 
This analysis of the D.E.S.I.R. study of 2,278 men and 2,314 women, was focused on the long term 
changes of SBP and DBP with age, between the ages of 30 and 65 years. While some participants were 
over 60 years at inclusion, D.E.S.I.R. did not include a "true" geriatric population. Indeed, it is well 
established in studies of CV epidemiology that around 55-60 years of age, the increase in SBP with age is 
associated with a progressive and consistent reduction of DBP with age [8-12]. In the present longitudinal 
study (Fig. 1A and B), we showed that both the mean values of SBP and DBP increased markedly with 
age-class and were influenced by sex, menopausal status and metabolic disorders (cholesterol, glycaemia, 
obesity, …). All these factors are usually associated with a shift of SBP and DBP toward higher BP values 
at each given age range. However, from the long term follow-up of D.E.S.I.R., another important factor 
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was shown for the first time: the rate of change in SBP or DBP per year with age differed markedly for 
each of the two parameters. This rate increased progressively as function of age for SBP, but in contrast, 
decreased significantly with age for DBP, as soon as the age of 40–45 years had been reached. Thereafter, 
the rate of change of DBP per year decreased progressively and markedly with increasing age. This finding 
was independent of sex, menopausal status and increased levels of BMI, waist circumference, plasma 
cholesterol, glucose and triglycerides. The only exception to this rule was the case of high BP, in which, 
particularly in men, the process of reduced ability to decrease DBP with age was consistently attenuated or 
even disappeared.  
This investigation was performed on the basis of non-invasive brachial BP measurements. 
A limitation of the study was that, primarily, a mercury sphygmomanometer was used for BP 
measurements, and, then after 3 years follow-up, an OMRON-device was used. However, in the present 
study, we accounted for this change and verified that it did not modify at all the classification of the overall 
population. Furthermore, our longitudinal study gave similar results to those previously obtained in the 
literature. In fact, as in all epidemiological reports, the principal limitation of the investigation was the site 
of BP measurements: the brachial artery [12]. Indeed, SBP is the most reproducible parameter to determine 
at the brachial artery site. However as a consequence of the presence of physiological SBP amplification, 
brachial SBP must be considered as a local parameter, which does not reflect central SBP measurements, 
except in subjects above 50 years of age without any tachycardia [11,12]. On the other hand, DBP, which is 
known to involve many errors in its measurement, is not a totally local parameter since its value is almost 
the same in the entire arterial tree. Brachial DBP may reflect adequately central DBP, and thus might be an 
index of the perfusion pressure of coronary arteries. In the present study, it is the change in DBP according 
to age, which was mostly studied. Thus, the errors of DBP measurements during the long-term follow-up 
might be largely minimized. On the other hand, it is well accepted that the OMRON device that was used 
for many of the measures in this study is known to predict very adequately the level of CV risk [15]. The 
D.E.S.I.R. cohort is not a population based study, but from a general French population; we believe these 
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results can be generalised to the population, taking into account the characteristics of the French Social 
Security System.  
The principal result of this investigation was obtained from the calculation of the mean change of 
SBP and DBP per unit year (ie. the rate of change) during the follow-up. Whereas the mean values of SBP 
and DBP both increased across the different age ranges, the rates of changes of SBP and DBP per year 
were strikingly dissociated. Across the age ranges, this change increased markedly with age for SBP but 
markedly decreased with age for DBP (Fig. 3A and 3B). The mathematical model was curvilinear for 
∆DBP with age, the maximum value being observed around 45 years and it then fell progressively for the 
higher ages. This evolution suggests an active process relating the reduction of DBP to vascular aging. This 
aspect differs from that of SBP but occurred similarly in men and women and was independent of 
traditional CV risk factors such as hypercholesterolemia, glycaemic status, BMI. Note that in the past, 
many studies have shown that the mean value of DBP decreased with age, but not the rate of change per 
unit age [8-12]. However, this decrease in the mean value of DBP with age before 55 years of age and was 
not observed in the present study because the cohort had only a very small geriatric population at inclusion.  
In the present study, the increase in the mean values of SBP and DBP with age was shifted toward 
higher values of SBP and DBP when studied by strata of traditional cardiovascular risk factors (such as 
higher BMI, diabetes mellitus, and increased cholesterol); the relations however remained parallel. In 
contrast, the relationship of the SBP or DBP slope with age was influenced exclusively by the presence of 
high BP, and not by any of the other cardiovascular risk factors. This finding might indicate that the 
presence of structural changes of arterioles and capillary rarefaction contributes consistently to maintain 
the elevated values of blood pressure in this population [16]. Further studies are needed to show which 
factors are responsible for the specific defect in the well-established process of DBP reduction with age. 
Perspectives 
This investigation has shown that, in a long-term follow-up, whereas for SBP the rate of change of the 
relationship increases progressively with age, for DBP the relationship begins to reduce as early as 45 
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years. The finding is independent of gender and metabolic disorders but disappears in the presence of 
hypertension at inclusion, particularly in men. Whether this particularity is influenced by drug treatment is 
yet difficult to determine and requires further investigations. 
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Figure legends  
 
Fig. 1A. Mean values of systolic blood pressure (SBP) mmHg by age (5 years), and sex: points 
indicate observed mean SBP by age class and the lines are the best-fit regressions; both the slope 
and the intercept differ significantly (P < 0.0001) between men and women. 
Fig. 1B. Mean values of diastolic blood pressure (DBP) mmHg by age (5 years), and sex: points 
indicate observed mean DBP by age class with the lines are the best-fit regressions; both the slope 
and the intercept differ significantly (P < 0.006, 0.001 respectively) between men and women. 
 
Fig. 2A. Mean values of systolic blood pressure (SBP) mmHg by age and sex, according to strata of 
blood pressure at inclusion. The slope and the intercept differ significantly between the strata for 
both men and women. 
Fig. 2B. Mean values of diastolic blood pressure (DBP) mmHg by age and sex. Only the intercepts 
differ significantly between the strata, for both men and women. 
 
Fig. 3A. Mean change per year (∆SBP) mmHg by age (5 years), and sex: points indicate observed 
mean changes per year by age class with the lines as the best-fit regressions; intercepts differed 
significantly (P = 0.0001) but identical curvature. 
Fig. 3B. Mean change per year (∆DBP) mmHg by age (5 years), and sex: points indicate observed 
mean changes per year by age class with the lines as the best-fit regressions; relations are identical 
for men and women. 
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Table 1. Characteristics [mean, (standard deviation) or n (%)] of the men and women at inclusion in 
the study, and the evolution of the parameters per year, assuming a linear increase. 
 
Variables Men (n=2,278) Women (n=2,314) P-value 
Baseline levels:    
Age (years) 47.1 (10.0) 47.1 (10.0) 0.8 
BMI (kg/m2)  25.4 (3.3) 24.0 (4.0) <0.0001 
Weight (kg)  75.8 (10.7) 61.1 (10.3) <0.0001 
Height (cm)  172.6 (6.5) 159.6 (6.0) <0.0001 
Waist circumference (cm) 89.7 (9.4)  77.1 (10.2) <0.0001 
 
Systolic blood pressure (mmHg) 134.5 (14.8) 127.8 (15.6) <0.0001 
Diastolic blood pressure (mmHg) 82.1 (9.5) 77.6 (9.0) <0.0001 
Treated for hypertension 234 (10%)  275 (12%)  0.08 
                           Beta blockers 94 (40%) 140 (51%) 0.01 
                                         ACE 102 (44%) 69 (25%) <0.0001 
                                  Diuretics 65 (28%) 96 (35%) 0.08 
       Calcium channel blockers 63 (27%) 43 (16%) 0.002 
Heart rate (beats per min)  66.4 (10.3) 68.2 (9.5) <0.0001 
 
Fasting glucose (mmol/l)  5.57 (0.86) 5.13 (0.76) <0.0001 
Cholesterol (mmol/l)   5.85 (1.01) 5.62 (0.97) <0.0001 
HDL-cholesterol (mmol/l) 1.48 (0.38) 1.78 (0.42) <0.0001 
Triglycerides (mmol/l) 1.37 (1.35) 0.97 (0.54) <0.0001 
 
Smoking (n, %)  
 
616 (27%) 
 
335 (14%) <0.0001 
Alcohol intake (g/day)  25.2 (24.8) 7.3 (11.4) <0.0001 
    
Postmenopausal (n,%)  878 (40%)  
Hormonal replacement therapy (n,%)  853 (38%)  
    
Change per year in:    
BMI (kg/m2) 0.11 (0.28) 0.15 (0.32) <0.0001 
Weight (kg) 0.27 (0.82) 0.32 (0.77) 0.06 
Waist circumference (cm)  0.32 (0.93) 0.45 (0.99) <0.0001 
 
Systolic blood pressure (mmHg)    
 
0.94 (2.49) 
 
0.53 (2.28)    
 
<0.0001 
Diastolic blood pressure (mmHg) 0.27 (1.59)    0.19 (1.43) 0.09 
Heart rate (beats per min) -0.22 (1.63) -0.18 (1.57) 0.3 
 
Fasting glucose (mmol/l) 
 
0.001 (0.13) 
 
-0.002 (0.10) 
 
0.4 
Cholesterol (mmol/l) -0.02 (0.14) 0.01 (0.13) <0.0001 
HDL-cholesterol (mmol/l) -0.01 (0.04) -0.01 (0.05) 0.0002 
Triglycerides (mmol/l) -0.001 (0.25)     0.01 (0.08) 0.03 
 
Alcohol intake (g/day)  
 
-0.38 (3.30)
 
-0.01 (1.43) 
 
<0.0001 
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TABLE 2. Equations for mean systolic and diastolic blood pressure (mmHg), according to age for men and women, by strata of cardio-metabolic 
risk factors. Abbreviations: see text. 
 
  SBP DBP 
  men women men women 
General relation  114 + 0.42 age 96 + 0.66 age 65 + 0.53 age - 0.0033 age2 57 + 0.60 age - 0.0033 age2 
      
BMI  < 25 kg/m² 115 + 0.36 age 97 + 0.60 age 72 + 0.17 age 56 + 0.63 age -0.0040 age2 
 ≥ 25 kg/m² 120 + 0.36 age* 103 + 0.60 age* 75 + 0.17 age* 59 + 0.63 age -0.0040 age2* 
      
Blood pressure SBP and DBP < 130/85 mmHg 117 + 0.051 age 109 + 0.17 age 69 + 0.12 age 58 + 0.58 age - 0.0052 age2 
 SBP or DBP ≥ 130/85 mmHg 126 + 0.31 age** 122 + 0.35 age** 80 + 0.12 age* 68 + 0.58 age - 0.0052 age2* 
      
Smoking non-smoker 114 + 0.42 age 96 + 0.67 age 72 + 0.21 age 57 + 0.61 age - 0.0036 age2 
 current 114 + 0.42 age 96 + 0.67 age 72 + 0.21 age 56 + 0.61 age - 0.0036 age2* 
      
Cholesterol ≤ 5.7 mmol/l 114 + 0.40 age 97 + 0.64 age 72 + 0.20 age 56 + 0.64 age - 0.0039 age2 
 > 5.7 mmol/l 117 + 0.40 age* 99 + 0.64 age* 74 + 0.20 age* 57 + 0.64 age - 0.0039 age2* 
      
Glucose status normal 116 + 0.38 age 97 + 0.65 age 73 + 0.18 age 56 + 0.65 age - 0.0040 age2 
 impaired fasting glucose 120 + 0.38 age 101 + 0.65 age 76 + 0.18 age 59 + 0.65 age - 0.0040 age2 
 diabetic 126 + 0.38 age* 101 + 0.65 age* 79 + 0.18 age* 59 + 0.65 age - 0.0040 age2* 
      
non-treated 117 + 0.34 age 99 + 0.59 age 73 + 0.18 age 55 + 0.70 age - 0.0047 age2 Anti-
hypertensive 
treatment 
treated 127 + 0.34 age* 108 + 0.59 age* 87 + 0.010 age* 59 + 0.70 age - 0.0047 age2* 
      
premenopausal  93 + 0.75 age  56 + 0.66 age - 0.0040 age2 Menopausal 
status postmenopausal  91 + 0.75 age  56 + 0.66 age - 0.0040 age2 
      
non treated  93 + 0.73 age  52 + 0.76 age - 0.0046 age2 Hormonal 
replacement 
therapy 
treated  101 + 0.58 age**  57 + 0.65 age - 0.0046 age2** 
 
*intercepts differ significantly between the strata of risk factors 
** intercepts and age coefficients differ significantly between the strata of risk factors 
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TABLE 3. Equations for rates of change of systolic (∆SBP) and diastolic (∆DBP) blood pressure (mmHg), according to age for men and 
women, by strata of metabolic risk factors. Abbreviations: see text. 
 
SBP DBP  
men women men women 
General relation  
 -2.07 + 0.10 age 
-0.00083 age2 
-2.48 + 0.10 age  
-0.00083 age2 
-1.02 + 0.068 age  
-0.00084 age2 
-1.02 + 0.068 age  
-0.00084 age2 
      
BMI  < 25 kg/m² -0.61 + 0.033 age -0.41 + 0.020 age 
-2.20 + 0.12 age -
0.0013 age2 
0.87 - 0.014 age 
 ≥ 25 kg/m² -0.61 + 0.033 age -0.41 + 0.020 age -2.20 + 0.12 age -
0.0013 age2 
0.87 - 0.014 age 
      
Blood pressure SBP and DBP < 130/85 mmHg -0.40 + 0.040 age -0.79 + 0.037 age 
-1.97 + 0.12 age -
0.0013 age2 
0.64 - 0.0043 age 
 SBP or DBP ≥ 130/85 mmHg -1.22 + 0.040 age* -1.68 + 0.037 age* -2.43 + 0.12 age -
0.0013 age2* 
0.11 - 0.0043 age* 
      
Smoking non -0.61 + 0.033 age -0.41 + 0.020 age 
-2.20 + 0.12 age -
0.0013 age2 
0.87 - 0.014 age 
 current -0.61 + 0.033 age -0.41 + 0.020 age 
-2.20 + 0.12 age -
0.0013 age2 
0.87 - 0.014 age 
      
Cholesterol ≤ 5.7 mmol/l -0.61 + 0.033 age -0.50 + 0.024 age -2.20 + 0.12 age -
0.0013 age2 
0.81 - 0.011 age 
 > 5.7 mmol/l -0.61 + 0.033 age -0.76 + 0.024 age* 
-2.20 + 0.12 age -
0.0013 age2 
0.63 - 0.011 age* 
      
Glucose status normal -0.87 + 0.037 age -1.20 + 0.033 age 
-3.84 + 0.18 age - 
0.0020 age2 
0.72 - 0.012 age 
 impaired fasting glucose -0.87 + 0.037 age -1.20 + 0.033 age 
-3.84 + 0.18 age - 
0.0020 age2 
0.72 - 0.012 age 
 diabetic -0.87 + 0.037 age -1.20 + 0.033 age 
-3.84 + 0.18 age - 
0.0020 age2 
0.72 - 0.012 age 
      
non-treated -0.61 + 0.033 age -0.58 + 0.025 age 
-2.20 + 0.12 age -
0.0013 age2 
0.76 – 0.011 age Anti-hypertensive 
treatment 
treated -0.61 + 0.033 age -1.19 + 0.025 age* -2.20 + 0.12 age - 0.40 – 0.011 age* 
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 0.0013 age2 
      
Menopausal status premenopausal  -0.41 + 0.020 age  0.87 - 0.014 age 
 postmenopausal  -0.41 + 0.020 age  0.87 - 0.014 age 
      
non treated  -0.41 + 0.020 age  0.87 - 0.014 age Hormonal 
replacement therapy treated  -0.41 + 0.020 age  0.87 - 0.014 age 
 
*intercepts differ significantly between the strata of risk factors  
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Figure 1B 
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Figure 2A 
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Figure 2B 
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Figure 3A 
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Figure 3B 
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